Access to Medicines – Page 18

Transparency is a fundamental pillar for the success of the EU Vaccines Strategy

by European Public Health Alliance | Dec 17, 2020 | Statements

39 civil society organisations including EPHA are calling on the European Commission and EU national governments to ensure a maximum degree of transparency in the EU’s exchanges, negotiations and deals with pharmaceutical companies over COVID19 vaccines, proposing a...

Getting it right: Recommendations for a European BARDA

by EPHA | Nov 29, 2020

Getting it right: Recommendations for a European BARDA  8 December 2020  16:00-17:00 CET  Online Our fifth dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics,...

The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines

by EPHA | Nov 24, 2020

The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines  25 November 2020  16:00-17:00 CET  Online Our fourth dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together...

Pharma & COVID19: Winners, losers, prospects

by EPHA | Nov 18, 2020

Pharma & COVID-19: Winners, losers, prospects  19 November 2020  16:00-17:00 CET  Online Our third dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry...

Putting medicines policy under the spotlight: EPHA’s #A2MDialogues

by European Public Health Alliance | Nov 14, 2020 | Opinion

Pharmaceutical policies and access to medicines top the policy agenda especially as the COVID19 challenges bring issues such as transparency in pharma, affordability of therapeutics, role of public support in biomedical innovation to the forefront. It is now more...